Nexien BioPharma Inc (PK) (NXEN) Share Price

Waste of time

Any particular reason this just shot up like a rocket?

What is ownthefloat sayin? I used to communicate with him quite a bit when I had facebook. I should trynl to get in touch with him.

Fingers crossed on this.
Been in since NTVA days. I know you have as well along with a few others.
TY

We shall see.....

https://x.com/OwnTheFloat/status/1840778396428648827

Thanks for the update Farmer

Yes, they replied and then I did a follow up about a month ago and they said they are actively in talks with another company that’s not on the exchange and wants to be. They have revenue I learned, not from the states, and have nothing to do with what they do which at this point I don’t care. This is all I know, but I fully intend to do a follow up in about two weeks. This obviously doesn’t happen overnight, so I’m giving it time. They can’t say much more than that, believe me I was prodding for more info. That’s ok though, keeps them out of trouble from saying something they shouldn’t. I’ll keep you posted, probably be around Labor Day. It does seem like they took my nasty message which involved a lot of advice to on selling their most valuable asset, which is being on the OTC. I met this crew several years ago, so I think they do respect my advice.

Was there any reply?

I sent them a nasty message a few months ago and told them to find a company with revenue that wants uplisted and make a run with them. It's not easy to get on the exchange these days with new laws, so that has value. I really believe they took my advice, because they are searching. Keep in
Mind I also said for then to get out of your box and think of companies that don't even do what you do, it's our only hope for shareholders.

I cannot believe I ever bought into this company. Does it even exist?

Check out Nugn and GDVM they have great possibilities.

It’s insanity after years of inactivity they do nothing

I think at this point their most valuable asset is being a public traded company in the OTCQB and should find a company of any kind with revenue and do a reverse merger. It's not ideal but would create some sort of liquidity for shareholders.

Looks like Evan picked up 4m shares.
Of what exactly?
No news from company in years.

Who is trading this stock everyday ?

What a POS with brain dead idiots running nothing - SELL THE SHELL !!!!!

Sell the shell and move on my god. What they think they are worth and what they're worth are two different things!

SOS anybody running this shit show

Sell the steaming POS of a company that has done nothing for years. How dumb are these morons.

Is Greenburg brain dead? He runs a public company that literally has done nothing in years. Just sell this POS as a shell

Diluting POS turd with no business

Sell the shell and end this turd

I only saw that shares were awarded to managers. No open market buys disclosed

Insiders all buying now

Sell this POS you brain dead retards. Shell is worth more then this zombie co.

10-k filed for period end 06/30/2022. https://www.otcmarkets.com/filing/html?id=16103240&guid=XIX-kH08gRLSJth

Lol they painted it down 500 shares
Zombie ticker

Dump away losers

Whoops! Very sorry!!!!

wrong company

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
First IND for NexImmune’s AIM nanoparticle platform in solid tumors
IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-related cancers
GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, has received IND clearance for the Company’s first cellular therapy product candidate addressing solid tumors. NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), is being developed for patients with relapsed or refractory human papillomavirus (HPV)-related cancers.

Kristi Jones, NexImmune’s CEO, commented, “The FDA clearance of our third IND marks another significant milestone for NexImmune and demonstrates our team’s continued focus and commitment to bringing novel therapies to patients with significant unmet need. NEXI-003 is our third T cell therapy and first candidate to address solid tumors. NEXI-003 consists of T cell populations simultaneously directed against multiple HPV tumor-relevant antigen targets. The T cells in our product candidate will consist of T cell subtypes critical to both potential anti-tumor activity and a phenotype intended to produce long-term immunologic memory required for durable responses.”

The Phase 1 trial will enroll patients at multiple clinical sites across the United States. The proposed study is a two-part, multicenter, open-label, dose-finding, first-in-human (FIH) study to characterize the safety and clinical activity of NexImmune’s HPV tumor-relevant antigen-specific CD8+ T cell product candidate (NEXI-003) in patients with relapsed or refractory locally advanced or metastatic HPV-related oropharyngeal cancers (with confirmed histopathology detection of HPV-16 and/or HPV-18 expression), who have received at least 1 prior regimen of standard therapy according to local standard of care guidance(s). The dose escalation phase will consist of multiple safety cohorts investigating increasing doses of NEXI-003 followed by an expansion phase that will enroll 24 to 36 patients overall, depending on the number of dose escalations. All patients will be followed for at least one year. Following initial data and after the recommended Phase 2 dose has been confirmed, NexImmune plans to expand the NEXI-003 development program to include other HPV related malignancies and evaluate potential SOC combination options across the patient populations.

About HPV-Related Cancers

Human papillomavirus (HPV)-related cancers are common epithelial malignancies that account for approximately 5% of all cancers globally. These cancers cause an estimated 12,500 deaths each year in the United States and more than 300,000 deaths each year throughout the world. Histologically, this family of cancers consists of squamous cell carcinomas and adenocarcinomas that occur in various anatomical sites including the oropharynx, uterine cervix, anus, vagina, vulva and penis. The high-risk HPV subtypes are most commonly HPV-16 and HPV-18. Malignant transformation results through the activation of the expression of the E6 and E7 HPV oncogenes, which inhibit the tumor suppressors p53 and Rb. These oncoproteins also inhibit apoptosis of tumor cells, deregulate the cell cycle, result in the accumulation of genetic instability, promote angiogenesis and facilitate the invasiveness and metastatic spread of cancerous cells.

About NexImmune

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least three prior lines of therapy, respective

Brain dead management

Very long term

Been a long wait

Hopefully another patent

They are overdue to make some announcement..

There it is flushed down the toilet POS

Stranger still seeing buyers with details about continuing research

S.253 - Cannabidiol and Marihuana Research Expansion Act

https://www.congress.gov/bill/117th-congress/senate-bill/253/text

This one was passed by the Senate and has more GOP support than Nadler's MORE Act that passed the House.

Yes, looks like we are starting to get some eyes on us. I would think we will hear that we are moving into a preclinical study fairly soon. Good results from that would bring in some big funding for the next level.

Nice find! This one is worth the long hold :)

NXEN mentioned alongside GWPH. It Seems things are starting to move.

https://www.advancemarketanalytics.com/reports/157542-global-cannabinoid-drugs-market

one more shake and we could see .25

Crazy thin L2

They could be shaking out the trees here... it has been a long time.
Something may be popping soon.. The SS is awesome.. I guess that is why we have been here for years.

Agree this is behind the action and hopefully we will get an announcement on the UPENN research.

Just days after the Senate passed a cannabis research bill, the House of Representatives has passed its own. Both bills aim to streamline, and, by extension, expand, cannabis research, but the two bills have some noteworthy differences.
https://cannabiswire.com/2022/04/04/cannabis-research-bills-advance-in-congress/

I guess the next couple days will reveal if today was a fluke?

Wow! What the heck happened here today? Big news on the horizon.

$NXEN WOW crazy thin